Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgkin lymphoma; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Central Nervous System Lymphoma
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• CD20-targeted CAR-T cell therapy (CD20-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-16